Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Orelabrutinib
Indication/Tumor Type CLL/SLL
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown CLL/SLL not applicable Orelabrutinib Phase II Actionable In a Phase II trial, treatment with Orelabrutinib (ICP-022) demonstrated safety and resulted in an objective response rate (ORR) of 88.5% (69/78), including 1 complete response, 39 partial responses, and 29 partial responses with lymphocytosis, and a 6 month duration of response of 89.8% in Chinese patients with relapsed or refractory chronic lymphocytic leukemia/small cell leukemia (Blood (2019) 134 (Supplement_1): 4319). detail...
PubMed Id Reference Title Details
Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia Full reference...